कंपनी का अवलोकन
Acumen Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing targeted therapies specifically for the treatment of Alzheimer's disease. The company functions within the broader healthcare sector and the specialized biotechnology industry, a landscape characterized by high research and development expenditures and long product development cycles. Acumen Pharmaceuticals, Inc. holds a market capitalization of $181.25M and employs a workforce of 60 individuals to advance its clinical pipeline. These financial figures indicate that the company maintains a mid-cap valuation typical of early-stage biotechnology firms that are capital-intensive and have not yet generated significant commercial revenue from their primary drug candidates.
वित्तीय स्वास्थ्य
The company reports a Net Income (TTM) of $-121,335,000 and an EBITDA of $-123,774,000, while Revenue (TTM) is listed as N/A, revealing a cost structure where operating expenses heavily outweigh any current income generation. This negative net income relative to the absence of reported revenue highlights the substantial investment required in research, development, and clinical trial costs inherent to the biotechnology sector. The Free Cash Flow stands at $-75,107,000, which signifies that the company is currently burning cash to fund its operations and development efforts rather than generating surplus liquidity from daily activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that revenue data is insufficient to calculate standard margins at this stage. On the liability side, the company holds $116.86M in cash against $31.31M in debt, resulting in a Debt to Equity ratio of 44.46, which suggests a highly leveraged balance sheet relative to equity but mitigated by a strong cash position. The Current Ratio is 4.07, indicating that the company possesses ample short-term assets to cover its short-term liabilities, providing a buffer for operational continuity despite the lack of profitability. Furthermore, the Return on Equity is -96.2% and the Return on Assets is -42.8%, metrics that reveal management is currently deploying capital in a manner that generates negative returns, a common characteristic for clinical-stage companies before product commercialization.
मूल्यांकन आकलन
The valuation metrics for Acumen Pharmaceuticals, Inc. include a P/E Ratio (TTM) of N/A and a Forward P/E of -1.80, where the negative forward multiple implies that analysts or models project continued losses in the near term rather than immediate earnings generation. The Price to Book ratio is 2.16, suggesting that the market values the company at a 116% premium over its book value, reflecting the potential worth of its intangible assets like intellectual property and drug candidates. Since Revenue is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA stands at -0.77, indicating that traditional earnings-based valuation multiples are not applicable and the company must be viewed through a cash-burn or asset-based lens. The stock's price volatility is bounded by a 52-Week High of $3.60 and a 52-Week Low of $0.85; based on the provided data ranges, the stock is trading within a range where the high of $3.60 represents the peak valuation observed in the last year. The Beta is 0.34, which means the stock's price volatility is significantly lower than the broader market, moving less than half as much as the market index in response to general market fluctuations.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning historical growth rates cannot be calculated due to the company's current stage of development and lack of consistent revenue history. Because the company is not a dividend payer, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the company retains all available cash flow to reinvest into its clinical trials and operational expansion rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms at the clinical stage, where capital is prioritized for advancing the Sabirnetug drug candidate rather than generating shareholder dividends. Consequently, the overall growth and income profile of Acumen Pharmaceuticals, Inc. is defined by negative financial returns and zero dividend income, relying entirely on external capital markets and internal cash reserves to fuel future development milestones.